查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530984

胃动力障碍药物市场（药物类别：抗酸剂、止泻药、钙通道阻断剂；以及疾病类型：上消化道和下消化道）- 全球产业分析、规模、份额、成长、趋势和预测，2024 -2034 年

Gastric Motility Disorder Drugs Market (Drug Class: Antacids, Antidiarrheals, Calcium-Channel Blockers; and Disorder Type: Upper Digestive Tract and Lower Digestive Tract) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 178 Pages | 商品交期: 2-10个工作天内

价格

胃动力障碍药物市场 - 报告范围

TMR 关于全球胃动力障碍药物市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。 2034 年期间的疾病药物市场，考虑2024 年为基准年，2034 年为预测年。报告中也提供了2024年至2034年全球胃动力障碍药物市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解胃动力障碍药物市场。

市场概况
2023年市场价值 576 亿美元
2034 年市场价值 1027 亿美元
复合年增长率 5.4%

该报告深入探讨了全球胃动力障碍药物市场的竞争格局。全球胃动力障碍药物市场的主要参与者已经确定，并且每位参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球胃动力障碍药物市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年市场分析与预测

第 5 章：主要见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依药物类别

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药品类别，2020-2034
    • 抗酸剂
    • 止泻药
    • 钙通道阻断剂
    • H2 阻断剂
    • 其他（质子帮浦抑制剂等）
  • 市场吸引力分析：依药品类别

第 7 章：全球市场分析与预测：按疾病类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依疾病类型，2020-2034
    • 上消化道
      • 贲门失弛缓症
      • 胃食道逆流症 (GERD)
      • 胃轻瘫
      • 倾倒综合症
    • 下消化道
      • 假性肠阻塞
      • 小肠细菌过度生长 (SIBO)
      • 骨盆协同失调
      • 先天性巨结肠症
  • 市场吸引力分析：依无序类型

第 8 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院药房
    • 零售药局
    • 网路药局
  • 市场吸引力分析：按配销通路

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第15章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Pfizer Inc.
    • The Takeda Pharmaceutical Company Limited
    • Janssen Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Boehringer Ingelheim
    • Eli Lilly and Company
    • The Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Bausch Health Companies Inc.
    • Mallinckrodt Pharmaceuticals
    • Endo International plc
    • Eisai Co. Ltd.
    • Ferring Pharmaceuticals
    • UCB
Product Code: TMRGL86200

Gastric Motility Disorder Drugs Market - Scope of Report

TMR's report on the global gastric motility disorder drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global gastric motility disorder drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gastric motility disorder drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the gastric motility disorder drugs market.

Market Snapshot
Market Value in 2023US$ 57.6 Bn
Market Value in 2034US$ 102.7 Bn
CAGR5.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gastric motility disorder drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global gastric motility disorder drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gastric motility disorder drugs market.

The report delves into the competitive landscape of the global gastric motility disorder drugs market. Key players operating in the global gastric motility disorder drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global gastric motility disorder drugs market profiled in this report.

Key Questions Answered in Global gastric motility disorder drugs Market Report:

  • What is the sales/revenue generated by gastric motility disorder drugs across all regions during the forecast period?
  • What are the opportunities in the global gastric motility disorder drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Gastric Motility Disorder Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global gastric motility disorder drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global gastric motility disorder drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global gastric motility disorder drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Gastric Motility Disorder Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Gastric Motility Disorder Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Antacids
    • 6.3.2. Antidiarrheals
    • 6.3.3. Calcium-channel Blockers
    • 6.3.4. H2 Blockers
    • 6.3.5. Others (Proton Pump Inhibitors, etc.)
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Disorder Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 7.3.1. Upper Digestive Tract
      • 7.3.1.1. Achalasia
      • 7.3.1.2. Gastroesophageal Reflux Disease (GERD)
      • 7.3.1.3. Gastroparesis
      • 7.3.1.4. Dumping Syndrome
    • 7.3.2. Lower Digestive Tract
      • 7.3.2.1. Intestinal Pseudo-obstruction
      • 7.3.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 7.3.2.3. Pelvic Dyssynergia
      • 7.3.2.4. Hirschsprung's Disease
  • 7.4. Market Attractiveness Analysis, by Disorder Type

8. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Class, 2020-2034
    • 10.3.1. Antacids
    • 10.3.2. Antidiarrheals
    • 10.3.3. Calcium-channel Blockers
    • 10.3.4. H2 Blockers
    • 10.3.5. Others (Proton Pump Inhibitors, etc.)
  • 10.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 10.4.1. Upper Digestive Tract
      • 10.4.1.1. Achalasia
      • 10.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 10.4.1.3. Gastroparesis
      • 10.4.1.4. Dumping Syndrome
    • 10.4.2. Lower Digestive Tract
      • 10.4.2.1. Intestinal Pseudo-obstruction
      • 10.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 10.4.2.3. Pelvic Dyssynergia
      • 10.4.2.4. Hirschsprung's Disease
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Class
    • 10.7.2. By Disorder Type
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Class, 2020-2034
    • 11.3.1. Antacids
    • 11.3.2. Antidiarrheals
    • 11.3.3. Calcium-channel Blockers
    • 11.3.4. H2 Blockers
    • 11.3.5. Others (Proton Pump Inhibitors, etc.)
  • 11.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 11.4.1. Upper Digestive Tract
      • 11.4.1.1. Achalasia
      • 11.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 11.4.1.3. Gastroparesis
      • 11.4.1.4. Dumping Syndrome
    • 11.4.2. Lower Digestive Tract
      • 11.4.2.1. Intestinal Pseudo-obstruction
      • 11.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 11.4.2.3. Pelvic Dyssynergia
      • 11.4.2.4. Hirschsprung's Disease
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Disorder Type
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Class, 2020-2034
    • 12.3.1. Antacids
    • 12.3.2. Antidiarrheals
    • 12.3.3. Calcium-channel Blockers
    • 12.3.4. H2 Blockers
    • 12.3.5. Others (Proton Pump Inhibitors, etc.)
  • 12.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 12.4.1. Upper Digestive Tract
      • 12.4.1.1. Achalasia
      • 12.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 12.4.1.3. Gastroparesis
      • 12.4.1.4. Dumping Syndrome
    • 12.4.2. Lower Digestive Tract
      • 12.4.2.1. Intestinal Pseudo-obstruction
      • 12.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 12.4.2.3. Pelvic Dyssynergia
      • 12.4.2.4. Hirschsprung's Disease
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Disorder Type
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Class, 2020-2034
    • 13.3.1. Antacids
    • 13.3.2. Antidiarrheals
    • 13.3.3. Calcium-channel Blockers
    • 13.3.4. H2 Blockers
    • 13.3.5. Others (Proton Pump Inhibitors, etc.)
  • 13.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 13.4.1. Upper Digestive Tract
      • 13.4.1.1. Achalasia
      • 13.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 13.4.1.3. Gastroparesis
      • 13.4.1.4. Dumping Syndrome
    • 13.4.2. Lower Digestive Tract
      • 13.4.2.1. Intestinal Pseudo-obstruction
      • 13.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 13.4.2.3. Pelvic Dyssynergia
      • 13.4.2.4. Hirschsprung's Disease
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Biopharmaceutical Companies
    • 13.5.3. Research Organizations and Academic Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Disorder Type
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Class, 2020-2034
    • 14.3.1. Antacids
    • 14.3.2. Antidiarrheals
    • 14.3.3. Calcium-channel Blockers
    • 14.3.4. H2 Blockers
    • 14.3.5. Others (Proton Pump Inhibitors, etc.)
  • 14.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 14.4.1. Upper Digestive Tract
      • 14.4.1.1. Achalasia
      • 14.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 14.4.1.3. Gastroparesis
      • 14.4.1.4. Dumping Syndrome
    • 14.4.2. Lower Digestive Tract
      • 14.4.2.1. Intestinal Pseudo-obstruction
      • 14.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 14.4.2.3. Pelvic Dyssynergia
      • 14.4.2.4. Hirschsprung's Disease
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Disorder Type
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. The Takeda Pharmaceutical Company Limited
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Janssen Pharmaceuticals
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Sun Pharmaceutical Industries Ltd.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. AbbVie Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Boehringer Ingelheim
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Eli Lilly and Company
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. The Bristol-Myers Squibb Company
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Daiichi Sankyo Company, Limited
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Bausch Health Companies Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Mallinckrodt Pharmaceuticals
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Endo International plc
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Eisai Co. Ltd.
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Ferring Pharmaceuticals
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview
    • 15.3.15. UCB
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. SWOT Analysis
      • 15.3.15.4. Financial Overview
      • 15.3.15.5. Strategic Overview

List of Tables

  • Table 01: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 03: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 05: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 07: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 08: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 11: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 12: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 15: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 16: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 19: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 20: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 23: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 24: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Drug Class, 2023
  • Figure 03: Global Gastric Motility Disorder Drugs Market Value Share, by Drug Class, 2023
  • Figure 04: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Disorder Type, 2023
  • Figure 05: Global Gastric Motility Disorder Drugs Market Value Share, by Disorder Type, 2023
  • Figure 06: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 07: Global Gastric Motility Disorder Drugs Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Gastric Motility Disorder Drugs Market Value Share, by Region, 2023
  • Figure 09: Global Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 11: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 13: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 14: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 22: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 23: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 26: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 31: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 32: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 35: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 40: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 41: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 44: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 49: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 50: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 53: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 58: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 59: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 62: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034